Impact 2020 Twitter Chat: Early-stage Funding, New Models for Success

Monday, March 24 2014
8:00 pm – 9:00 pm

Location: #Impact2020 & @MassBio on Twitter or TweetChat

MassBio continues its #Impact2020 Twitter Chat Series with a focus on the evolution of early-stage funding in life sciences. From pharma-based venture funds to advocacy group-directed research to crowd-funding, we’re in the midst of a sea change in how emerging biotechs find funding and address capital challenges. The IPO window reopened in 2013 but how long can we expect it to stay open? With a significant decline in seed stage funding, are Massachusetts’ good ideas being funded? How do we continue to support fledgling companies that need startup money for early research or proof-of-concept?

To join the conversation, follow #impact2020 on Monday, March 24 from 8-9 pm ET.

MassBio #Impact2020 brings together an interesting mix of experts and observers across life science sectors to discuss hot topics facing the industry. David Berry of Flagship Ventures (@FlagshipVenture) and @MassBio’s John Hallinan will be our guest moderators for this month’s MassBio’s ongoing Twitter conversation.

We look forward to chatting with you on Monday, March 24 from 8-9 p.m.

What: MassBio Impact 2020 Twitter Chat

When: Monday, March 24, 8-9 pm ET

Why:  Lend your voice, get a sneak previous of MassBio’s Impact 2020 Report

Where: Follow #Impact2020 on Twitter or through to join our Chat Room


About The Moderators

David Berry joined Flagship in 2005 where he focuses on innovating, entrepreneuring, and investing in new ventures in life sciences and sustainability.  He is a founder of Flagship portfolio companies Joule Unlimited, Eleven Biotherapeutics, Seres Health, Pronutria, among others.  David was founding CEO of Joule and Pronutria.  He was also a Board member of Flagship portfolio company CGI Pharmaceuticals (acquired by Gilead in 2010), and currently serves on the boards of Joule, Eleven, Seres and Pronutria. David previously completed his combined MD-PhD from Harvard Medical School and the MIT Biological Engineering Division in just over 5 years. 

He has been recognized with over 50 awards and honors as an innovator including receiving the prestigious Lemelson-MIT Student Prize for invention and innovation, being named the Innovator of the Year by Technology Review, and being selected by the US State Department as 1 of 12 Innovators Helping to Reshape Realty.  He also speaks across the globe on topics including innovation, sustainability, biotechnology, and entrepreneurship, including at the National Academies, for the Prince of Girona Foundation, and at Google Solve for X.  David previously served on the MIT Corporation, its Board of Trustees, and currently serves on the boards of multiple not-for-profits in education and the arts, and has been appointed to the United Nations Sustainable Development Solution Network Leadership Council.

John Hallinan joined MassBio in 2012 as the Chief Business Officer and oversees the MassBio Innovation Services programs.

John’s fiscal experience in the life sciences and software industries reflect positions of increasing responsibility across a broad range of strategic and operational disciplines. His background encompasses venture financings, corporate development, technology licensing, and mergers and acquisitions.

Prior to MassBio, John was the Chief Financial Officer at Cytel, a leader in the design and implementation of adaptive clinical trials, and he had been active with MassBio—serving on the Economic Development Advisory Group and as co-chair of the Finance Committee & Entrepreneur’s University.


Share MassBio